| CAS登錄號 | 中文名 | 英文名 | 分子結構式 | 分子式 | 詳情 | 供應商 |
| 130469-38-4 | Adenosine,2',3'-dideoxy-3'-(hydroxymethyl)- (9CI) |  | C11H15N5O3 | 詳情 | 供應商 | |
| 76227-25-3 | Adenosine,2'-deoxy-3-methyl- (9CI); 3-Methyl-2'-deoxyadenosine |  | C11H15N5O3 | 詳情 | 供應商 | |
| 130469-39-5 | Adenosine,2',3'-dideoxy-2'-(hydroxymethyl)- (9CI) |  | C11H15N5O3 | 詳情 | 供應商 | |
| 55073-83-1 | a-D-Xylofuranoside, methyl3-(6-amino-9H-purin-9-yl)-3,5-dideoxy- (9CI); NSC196561 |  | C11H15N5O3 | 詳情 | 供應商 | |
| 26383-05-1 | Adenosine,3'-deoxy-3'-methyl-; 3'-Deoxy-3'-methyladenosine; NSC 127970 |  | C11H15N5O3 | 詳情 | 供應商 | |
| 2002-35-9 | Adenosine,2'-deoxy-N-methyl-; 2'-Deoxy-N6-methyladenosine; 6-(Methylamino)purine deoxyriboside; N6-Methyl-2'-deoxyadenosine; N6-Methyldeoxyadenosine |  | C11H15N5O3 | 詳情 | 供應商 | |
| 153185-55-8 | D-erythro-Pentitol,1-(6-amino-9H-purin-9-yl)-1,4-dideoxy-4-methylene- (9CI); AcycloneplanocinA |  | C11H15N5O3 | 詳情 | 供應商 | |
| 19186-33-5 | 芒雷素 | 1,2-Cyclopentanediol,5-(6-amino-9H-purin-9-yl)-3-(hydroxymethyl)-, (1S,2R,3R,5R)-; 1,2-Cyclopentanediol,3-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)-, (1R,2S,3R,5R)- (8CI,9CI); 1,2-Cyclopentanediol, 3-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)-, [1R-(1a,2a,3b,5b)]-; (-)-Aristeromycin; 1'a-Carbaadenosine; Aristeromycin; C-Adenosine; Carbocyclic adenosine; Cycloadenosine; NSC 103526 |  | C11H15N5O3 | 詳情 | 供應商 |
| 30958-52-2 | 1H-Purine-2,6-dione,3,7-dihydro-3,7-dimethyl-8-(4-morpholinyl)-; Theobromine,8-morpholino- (7CI,8CI) |  | C11H15N5O3 | 詳情 | 供應商 | |
| 28557-24-6 | 1H-Imidazo[2,1-f]purine-2,4(3H,6H)-dione,7,8-dihydro-8-(2-hydroxyethyl)-1,3-dimethyl- (8CI,9CI); 1-(2-Hydroxyethyl)-6,8-dimethylimidazolino[1,2-f]xanthine; KT 119 |  | C11H15N5O3 | 詳情 | 供應商 | |
| 249503-33-1 | 3,4-Pyrrolidinediol,2-(hydroxymethyl)-5-(9H-purin-9-ylmethyl)-, (2R,3R,4S,5S)-; 3,4-Pyrrolidinediol, 2-(hydroxymethyl)-5-(9H-purin-9-ylmethyl)-, (2R,3R,4S,5S)- |  | C11H15N5O3 | 詳情 | 供應商 | |
| 249503-25-1 | 3,4-Pyrrolidinediol,2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-, (2S,3S,4R,5R)-; ImmucillinA |  | C11H15N5O3 | 詳情 | 供應商 | |
| 91296-12-7 | 6H-Purin-6-one,2-amino-1,9-dihydro-9-[(1R,3S,4R)-3-hydroxy-4-(hydroxymethyl)cyclopentyl]-,rel-; 6H-Purin-6-one,2-amino-1,9-dihydro-9-[3-hydroxy-4-(hydroxymethyl)cyclopentyl]-, (1a,3b,4a)-(?à)-; 6H-Purin-6-one,2-amino-1,9-dihydro-9-[3-hydroxy-4-(hydroxymethyl)cyclopentyl]-, (1a,3b,4a)-; NSC 260601 |  | C11H15N5O3 | 詳情 | 供應商 | |
| 130368-81-9 | 6H-Purin-6-one,2-amino-9-[3,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro- |  | C11H15N5O3 | 詳情 | 供應商 | |
| 126373-87-3 | 6H-Purin-6-one,2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-, rel-; 6H-Purin-6-one,2-amino-9-[2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-, (1a,2b,3a)-(?à)-; (?à)-Cyclobut-G; (?à)-Lobucavir; 6H-Purin-6-one,2-amino-9-[2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-, (1a,2b,3a)-; Cyclobut G; SQ 33054 |  | C11H15N5O3 | 詳情 | 供應商 | |
| 126062-18-8 | 6H-Purin-6-one,2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-, rel-; 6H-Purin-6-one,2-amino-9-[2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-, (1a,2b,3a)-(?à)-; (?à)-Cyclobut-G; (?à)-Lobucavir; 6H-Purin-6-one,2-amino-9-[2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-, (1a,2b,3a)-; Cyclobut G; SQ 33054 |  | C11H15N5O3 | 詳情 | 供應商 | |
| 127759-89-1 | 6H-Purin-6-one,2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-; 6H-Purin-6-one,2-amino-9-[2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-, [1R-(1a,2b,3a)]-; (+)-Cyclobut G; BMS 180194; Lobucavir; SQ 34514 |  | C11H15N5O3 | 詳情 | 供應商 | |
| 120386-10-9 | 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidicacid, 4-amino-7-[(2-hydroxyethoxy)methyl]-, methyl ester |  | C11H15N5O3 | 詳情 | 供應商 | |
| 171813-08-4 | 9H-Imidazo[1,2-a]purin-9-one,6,7-diethyl-3,5,6,7-tetrahydro-6,7-dihydroxy-; 9H-Imidazo[1,2-a]purin-9-one,6,7-diethyl-1,4,6,7-tetrahydro-6,7-dihydroxy- (9CI) |  | C11H15N5O3 | 詳情 | 供應商 | |
| 289665-54-9 | (2R,3R,4S)-4-(6-AMINO-9H-PURIN-9-YL)-2-(2-HYDROXYETHYL)-TETRAHYDROFURAN-3-OL |  | C11H15N5O3 | 詳情 | 供應商 | |